Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Kory et al., FLCCC Alliance
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 69% Improvement Relative Risk Ivermectin for COVID-19  Kory et al.  META ANALYSIS c19ivm.org Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been widely used, showing efficacy of ivermectin in prophylaxis and treatment of COVID-19.
There is potentially inaccurate data collection and/or reporting in some included trials.
7 meta analyses show significant improvements with ivermectin for mortality1-6, hospitalization7, recovery3, and cases3.
Currently there are 104 ivermectin for COVID-19 studies, showing 48% lower mortality [35‑59%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 81% fewer cases [71‑87%].
risk of death, 69.0% lower, RR 0.31, p < 0.001, treatment 35 of 1,551 (2.3%), control 191 of 1,957 (9.8%), NNT 13, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kory et al., 18 Dec 2020, preprint, 10 authors.
This PaperIvermectinAll
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
MD, MPA Pierre Kory, MD G Umberto Meduri, Jose Iglesias, Do, MD Joseph Varon, MD Keith Berkowitz, MD Howard Kornfeld, MD Eivind Vinjevoll, MBChB Scott Mitchell, MD Fred Wagshul, MD Paul E Marik
In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties against COVID-19. They then identified repeated, consistent, large magnitude improvements in clinical outcomes in multiple, large, randomized and observational controlled trials in both prophylaxis and treatment of data showing impacts on population wide health outcomes have Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 [FLCCC Alliance; updated Jan 16, 2021] 2 / 30 www.flccc.net resulted from multiple, large "natural experiments" that occurred when various city mayors and regional health ministries within South American countries initiated "ivermectin distribution" campaigns to their citizen populations in the hopes the drug would prove effective. The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin may prove to be a global solution to the pandemic. This was further evidenced by the recent incorporation of ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Belize, Macedonia, and the state of Uttar Pradesh in Northern India, populated by 210 million people. To our knowledge, the current review is the earliest to compile sufficient clinical data to demonstrate the strong signal of therapeutic efficacy as it is based on numerous clinical trials in multiple disease phases. One limitation is that half the controlled trials have been published in peer-reviewed publications, with the remainder taken from manuscripts uploaded to medicine pre-print servers. Although it is now standard practice for trials data from pre-print servers to immediately influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a result of this practice, the FLCCC argues that it is imperative that our major national and international health care agencies devote the necessary resources to more quickly validate these studies and confirm the major, positive epidemiological impacts that have been recorded when ivermectin is widely distributed among populations with a high incidence of COVID-19 infections. 1 https://www.flccc.net Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 [FLCCC Alliance; updated Jan 16, 2021] 3 / 30 5 https://trialsitenews.com/an-old-drug-tackles-new-tricks-ivermectin-treatment-in-three-brazilian-towns/ 6 https://www.who.int/publications/i/item/WHOMVPEMPIAU201907 Review of the..
It is the authors opinion, that based on the totality of these data, the use of ivermectin as a prophylactic and early treatment option should receive an A-I level recommendation by the NIH in support of use by the nation's health care providers. When, or if, such a recommendation is issued, the Front Line COVID-19 Critical Care Alliance has developed a prophylaxis and early treatment protocol for COVID-19 (I-MASK+), centered around ivermectin combined with masking, social distancing, hand hygiene, Vitamin D, Vitamin C, quercetin, melatonin, and zinc, with all components known for either their anti-viral, anti-inflammatory, or preventive actions (Table 4 ). The I-MASK+ protocol suggests treatment approaches for prophylaxis of high-risk patients, post-exposure prophylaxis of household members with COVID-19, and an early treatment approach for patients ill with COVID-19. Contribution to the field statement COVID-19 has caused a worldwide pandemic that has caused over 1.5 million global deaths along with continued rising case counts, lockdowns, unemployment and recessions in multiple countries. In response, the Front Line COVID-19 Critical Care Alliance (FLCCC), formed early in the pandemic, began to review the rapidly emerging basic science, translational, and clinical data to develop effective treatment protocols. The supportive evidence and rationale for their highly effective hospital treatment protocol called "MATH+" was recently published in a major medical..
References
Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Aguirre-Chang, Post-Acute or prolonged COVID-19: treatment with ivermectin for patietns with persistent, or post-acute symptoms ResearchGate
Ahmed, Karim, Ross, Hossain, Clemens et al., A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, International Journal of Infectious Diseases
Alam, Pf, Md, Ma, Ivermectin as Pre-exposure Prophylaxis for COVID 19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka An Observational Study, European Journal of Medical and Health Sciences
Anglemyer, Horvath, Bero, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, Cochrane Database Syst Rev
Arevalo, Pagotto, Porfido, Daghero, Segovia et al., Ivermectin reduces coronavirus infection in vivo: a mouse experimental model, bioRxiv
Atkinson, Audsley, Lieu, Marsh, Thomas et al., Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V, Scientific Reports
Babalola, Bode, Ajayi, Alakaloko, Akase et al., Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos, medRxiv
Behera, Patro, Singh, Chandanshive, Ravikumar et al., Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
Bernigaud, Guillemot, Ahmed-Belkacem, Grimaldi-Bensouda, Lespine et al., Bénéfice de l'ivermectine: de la gale à la COVID-19, un exemple de sérendipité
Bray, Rayner, Noël, Jans, Wagstaff, Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Research
Budhiraja, Soni, Jha, Indrayan, Dewan et al., Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience
Cadegiani, Goren, Wambier, Mccoy, Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide
Callard, Perego, Caly, Druce, Catton et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Social Science & Medicine
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research
Carvallo, Hirsch, Farinella, Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Carvallo, Roberto, Psaltis, Veronica, Study of the Efficacy and Safety of Topical Ivermectin+ Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel
Castillo, Entrenas Costa, Vaquero Barrios, Alcala Diaz, Lopez Miranda et al., Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study, J Steroid Biochem Mol Biol
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms
Chachar, Khan, Asif, Tanveer, Khaqan et al., Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients, International Journal of Sciences
Chala, Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc
Chamie, Chandler, Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?, The American journal of tropical medicine and hygiene
Chowdhury, Shahbaz, Karim, Islam, Guo et al., A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
Ci, Li, Yu, Zhang, Yu et al., Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol
Consortium, Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results
Crump, Omura, Ivermectin,'wonder drug'from Japan: the human use perspective, Proceedings of the Japan Academy, Series B
Dahabreh, Sheldrick, Paulus, Chung, Varvarigou et al., Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes, European Heart Journal
Dasgupta, Bakshi A, Dasgupta A, Manna, Saha, De et al., Nsp7 and Spike Glycoprotein of SARS-CoV-2 Are Envisaged as Potential Targets of Vitamin D and Ivermectin, Preprints
Dayer, Coronavirus (2019-nCoV) Deactivation via Spike Glycoprotein Shielding by Old Drugs, Bioinformatic Study
De Melo, Lazarini, Larrous, Feige, Kergoat et al., Anti-COVID-19 efficacy of ivermectin in the golden hamster, bioRxiv
Elgazzar, Hany, Youssef, Hafez, Moussa, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Espitia-Hernandez, Munguia, Diaz-Chiguer, Lopez-Elizalde, Jimenez-Ponce et al., Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: a proof of concept study, The Lancet
Gorial, Mashhadani, Sayaly, Dakhil, Almashhadani et al., Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). medRxiv. Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, FLCCC Alliance
Gupta, Biswal, Panda, Ray, Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin, J Biomol Struct Dyn
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects, Journal of clinical pharmacology
Götz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Scientific Reports
Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad
Hellwig, Maia, A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin, Int J Antimicrob Agents
Hermine, Mariette, Tharaux, Resche-Rigon, Porcher et al., Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial, JAMA Intern Med
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with Covid-19-preliminary report, The New England journal of medicine
Hussien, Abdelaziz, Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease, Network Modeling Analysis in Health Informatics and Bioinformatics
Jehi, Ji, Milinovich, Erzurum, Rubin et al., Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing: Results From 11,672 Patients, Chest
Kalfas, Visvanathan, Chan, Drago, THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A REVIEW OF MECHANISMS AND EVIDENCE
Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19, Archivos de Bronconeumología
King, Tessier, Dodge, Weinberg, Mymryk, Inhibition of Human Adenovirus Replication by the Importin α/β1 Nuclear Import Inhibitor Ivermectin, Journal of Virology
Kircik, Del Rosso, Layton, Schauber, Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications, Journal of drugs in dermatology : JDD
Kitsios, Dahabreh, Callahan, Paulus, Campagna et al., Can We Trust Observational Studies Using Propensity Scores in the Critical Care Literature? A Systematic Comparison With Randomized Clinical Trials, Crit Care Med
Kory, Meduri, Iglesias, Varon, Marik, Clinical and Scientific Rationale for the "MATH+" Hospital Treatment Protocol for COVID-19, Journal of Intensive Care Medicine
Lehrer, Rheinstein, Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2, Vivo
Li, Chen, Cao, Zhu, Zheng et al., Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response, Microbes Infect
Lonjon, Boutron, Trinquart, Ahmad, Aim et al., Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures, Ann Surg
Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Research
Mahmud, A Randomized, Double-Blind Placebo Controlled Clinical Trial of Ivermectin plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Marik, Kory, Varon, Iglesias, Meduri, MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale, Expert Review of Anti-infective Therapy
Mastrangelo, Pezzullo, De Burghgraeve, Kaptein, Pastorino et al., Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, Journal of Antimicrobial Chemotherapy
Maurya, A combination of ivermectin and doxycycline possibly blocks the viral entry and modulate the innate immune response in COVID-19 patients
Morgenstern, Redondo, De Leon, Canela, Torres et al., The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group
Nadkarni, Lala, Bagiella, Chang, Moreno et al., Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19, J Am Coll Cardiol
Nallusamy, Mannu, Ravikumar, Angamuthu, Nathan et al., Shortlisting Phytochemicals Exhibiting Inhibitory Activity against Major Proteins of SARS-CoV-2 through Virtual Screening
Niaee, Gheibi, Namdar, Allami, Zolghadr et al., Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
Perera, Tso, Tsang, Tsang, Fung et al., SARS-CoV-2 virus culture from the upper respiratory tract: Correlation with viral load, subgenomic viral RNA and duration of illness, MedRXiv
Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC J. Med. Sci
Polak, Van Gool, Cohen, Von Der Thusen, Van Paassen, A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression, Mod Pathol
Portmann-Baracco, Bryce-Alberti, Accinelli, Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in Covid-19
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19
Ravikirti, Pattadar, Raj, Agarwal, Biswas et al., Ivermectin as a potential treatment for mild to moderate COVID-19 -A double blind randomized placebo-controlled trial, medRxiv
Robin, Alam, Saber, Bhiuyan, Murshed et al., A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline, Journal of Bangladesh College of Physicians and Surgeons
Rodriguez-Nava, Trelles-Garcia, Yanez-Bello, Chung, Trelles-Garcia et al., Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study, Crit Care
Rubin, As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts, JAMA
Salvarani, Dolci, Massari, Merlo, Cavuto et al., Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial
Schmith, Zhou, Lohmer, The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19, Clinical Pharmacology & Therapeutics
Shouman, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient with COVID-19, Clincal Trials
Siegelman, Soto-Becerra, Culquichicón, Hurtado-Roca, Araujo-Castillo, Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. Azithromycin, and Ivermectin Among Hospitalized COVID-19 Patients: Results of a Target Trial Emulation Using Observational Data from a Nationwide Healthcare System in Peru
Sparsa, Bonnetblanc, Peyrot, Loustaud-Ratti, Vidal et al., Systemic adverse reactions with ivermectin treatment of scabies, Annales de Dermatologie et de Venereologie)
Spoorthi, Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV2, International Archives of Integrated Medicine
Suravajhala, Parashar, Malik, Nagaraj, Padmanaban et al., Comparative Docking Studies on Curcumin with COVID-19 Proteins
Swargiary, Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies
Tambo, Khater, Chen, Bergquist, Zhou, a great boost towards elimination of the global infectious diseases of poverty
Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Research
Varghese, Kaukinen, Gläsker, Bespalov, Hanski et al., Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antiviral Research
Veit, Beck, Steuerwald, Hatz, First case of ivermectin-induced severe hepatitis, Transactions of the Royal Society of Tropical Medicine and Hygiene
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochemical Journal
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer
Zhang, Qin, Cheng, Shen, Zhao et al., Inhospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19, Cell metabolism
Zhang, Rao, Li, Zhu, Liu et al., High-dose vitamin C infusion for the treatment of critically ill COVID-19
Zhang, Song, Ci, An, Ju et al., Ivermectin inhibits LPSinduced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res
Zhang, Song, Xiong, Ci, Li et al., Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit